Key Takeaway: Liquidia Corporation has announced that it will report its financial results for the second quarter of 2026 on August 12, 2026. The company, based in Morrisville, N.C., is dedicated to advancing care for patients with complex respiratory and vascular conditions. This announcement reflects the company's ongoing commitment to transparency in its financial performance.
Price reaction · baseline $86.82 (2026-07-28 close) · hit pre-market · clean, no other LQDA news in the window
day 0 close
0%
Market Sentiment Analysis
POSITIVE FACTORS
Liquidia Corporation is committed to improving patient care.
The company is focused on addressing challenging respiratory and vascular diseases.
Reporting financial results indicates transparency and accountability.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+71%
120-day peak, hindsight
Typical move
5%
average across 2 past catalysts
Lead asset
L606
Phase 3 · Pulmonary Arterial Hypertension
Full Press Release Details
MORRISVILLE, N.C., July 29, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, announced today that it will report its second quarter 2026
Frequently Asked Questions
When will Liquidia report its Q2 2026 financial results?
Liquidia Corporation will report its Q2 2026 financial results on August 12, 2026.
What is Liquidia Corporation focused on?
Liquidia Corporation is focused on revolutionizing care for patients with respiratory and vascular diseases.